Physician profile
Jon M Rich
NPI 1770520942
$7,715.42
in general payments reported to CMS, 2019-2025
34 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,309 · 2020: $908 · 2021: $1,704 · 2022: $1,487 · 2023: $1,515 · 2024: $589 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,307.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $912.44 | 2019-2024 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $696.97 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $691.98 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $609.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $572.34 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $518.72 | 2019-2025 | |
| Radius Health, INC. | $499.45 | 2019-2024 | Tymlos |
| Mylan Specialty L.P. | $375.76 | 2019-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $366.31 | 2021-2024 | Rexulti, Nuedexta |
| Lilly USA, LLC | $347.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $289.53 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.35 | 2019-2024 | Xifaxan |
| Dexcom, INC. | $153.77 | 2021-2024 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $149.48 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $129.42 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $125.88 | 2019-2023 | Livalo |
| Janssen Pharmaceuticals, INC | $125.51 | 2020-2023 | Xarelto |
| Genentech USA, INC. | $123.00 | 2019-2022 | |
| Abbvie INC. | $116.64 | 2021-2023 | |
| Antares Pharma, INC. | $109.37 | 2024 | Xyosted |
| Sunovion Pharmaceuticals INC. | $94.17 | 2019-2020 | |
| Nevro Corp. | $85.84 | 2022-2023 | Senza |
| Exact Sciences Corporation | $85.74 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $56.81 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.09 | 2022 | |
| Allergan, INC. | $46.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $43.03 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.94 | 2021 | |
| Ironshore Pharmaceuticals INC. | $18.27 | 2023 | Jornay Pm |
| Ironwood Pharmaceuticals, INC | $17.14 | 2020 | |
| Axsome Therapeutics, INC. | $15.06 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $14.66 | 2023 | Quviviq |
| Cranial Technologies, INC | $13.28 | 2024 | Doc Band |
| Shield Therapeutics INC | $13.02 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.